Lenalidomid Teva

Lenalidomide, the active ingredient in Lenalidomid Teva, is an immunomodulatory agent presented as an oral tablet for oral use. It is indicated for the treatment of certain hematologic malignancies, specifically multiple myeloma and myelodysplastic syndromes, in adult patients. The product is authorized in the European Union and is available by prescription only.

GNH USA supplies Lenalidomid Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, ensuring regulatory‑aligned sourcing and reliable logistics for clinical use.

Lenalidomide is used in the management of hematologic malignancies, targeting abnormal plasma cells and dysplastic bone‑marrow clones.

- Multiple myeloma: Improves progression‑free survival and overall response rates in patients with newly diagnosed or relapsed disease. - Myelodysplastic syndromes (MDS) with del(5q): Reduces transfusion dependence and can induce cytogenetic remission. - Relapsed or refractory disease: Provides therapeutic benefit when other treatments have failed.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: Decreased neutrophil count, increasing infection risk. - Thrombocytopenia: Low platelet levels, leading to bleeding tendencies. - Fatigue: Generalized tiredness affecting daily activities. - Nausea: Stomach upset, sometimes accompanied by vomiting. - Rash: Mild skin irritation or erythema. - Constipation: Reduced bowel movements causing discomfort.

Serious or Rare Side Effects: - Venous thromboembolism: Deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia: Marked infection risk requiring medical intervention. - Severe thrombocytopenia: Potential for serious hemorrhage. - Secondary primary malignancies: Development of new cancers. - Stevens‑Johnson syndrome: Severe skin reaction with blistering. - Hepatic failure: Significant liver enzyme elevation or dysfunction.

Before initiating therapy, clinicians should assess several safety considerations.

- Blood count monitoring: Perform baseline and regular CBC to detect cytopenias. - Thrombotic risk assessment: Evaluate history of clotting disorders and consider prophylactic anticoagulation. - Pregnancy avoidance: Contraindicated in pregnancy; ensure effective contraception. - Renal function adjustment: Dose may need modification in patients with impaired renal clearance. - Drug interaction review: Check for concomitant CYP3A4 modulators and anticoagulants. - Store below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide interacts with several medication classes that may alter its safety or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Increase lenalidomide exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Decrease drug levels, reducing effectiveness. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): Heighten bleeding risk.

Moderate Interactions (Monitor Closely): - P‑glycoprotein substrates (e.g., digoxin): May experience altered plasma concentrations. - Immunosuppressants (e.g., cyclosporine): Potential additive immunosuppression. - Vaccines (live attenuated): Reduced vaccine efficacy; consider timing of administration.